Other TAXUS Stent Data Presentations
-- The following e-poster presentations will highlight additional safety
and efficacy data from Boston Scientific's comprehensive TAXUS clinical
-- "Paclitaxel-Eluting Stents Are Effective in Higher Risk Patients:
Gender and Age Specific Sub-Group Analyses of the TAXUS OLYMPIA
Registry" -- (Dr. Oscar Mendiz, et al., moderated e-poster session,
March 29, 8:00 a.m.)
-- "Drug-Eluting Stents and Acute Myocardial Infarction: Experience from
the TAXUS ARRIVE Registry Program" -- (Dr. John Lasala, et al., e-
poster session, March 29, 8:00 a.m.)
-- "Predictors of Stent Thrombosis and Revascularization in Real-World Use
of the TAXUS Express2 Paclitaxel-Eluting Stent: Insights from the
7,300-Patient ARRIVE Program" -- (Dr. John Lasala, et al., moderated e-
poster session, March 29, 2:00 p.m.)
Boston Scientific will present its latest cardiovascular products at booth #18077 in the Exhibit Hall, including its drug-eluting stent and cardiac rhythm management technologies. The booth will also include product and program displays offering physician and patient resources.
TAXUS, Express, Express2 and PROMUS are trademarks of Boston Scientific Corporation or its affiliates. XIENCE is a trademark of Abbott. The SPIRIT Clinical Program is sponsored by Abbott. The PROMUS/XIENCE V Stents are investigational devices and are limited by federal law to investigational use. Premarket Approval (PMA) applications for these stents are currently under review by the U.S. Food and Drug Administration. The PROMUS/XIENCE V Stents are not for sale in the United States or Japan.
Boston Scientific is a worldwide developer, manufacturer and marketer
of medical devices whose products are used in a broad range of
interventional medical specialties. For more information, please visit:
|SOURCE Boston Scientific Corporation|
Copyright©2008 PR Newswire.
All rights reserved